Cytek Biosciences, Inc. expected to post a loss of 8 cents a share - Earnings Preview

Cytek Biosciences

04/08/2026 01:15

Cytek Biosciences, Inc. CTKB.OQ CTKB.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Fremont California-based  company is expected to report a 6.6% increase in revenue to $48.61 million from $45.6 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Cytek Biosciences, Inc. is for a loss of 8 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Cytek Biosciences, Inc. is $5.25, about 21.8% above its last closing price of $4.31
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.09
-0.10
-0.15
Missed
-55.2
Dec. 31 2026
-0.04
-0.02
-0.04
Missed
-100
Sep. 30 2025
-0.06
-0.05
-0.04
Beat
23.8​
Jun. 30 2025
-0.08
-0.07
-0.04
Beat
42.9
​​Mar. 31 2025
-0.04
-0.04
-0.09
Missed
-100
Dec. 31 2024
0.05
0.05
0.07
Beat
34.6​
Sep. 30 2024
-0.02
-0.01
0.01
Beat
166.7
Jun. 30 2024
-0.03
-0.03
-0.08
Missed
-166.7
This summary was machine generated August 4 at 00:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)